HK이노엔(195940) IR & PR 공식채널

HK inno.N Ranked No. 1 in Sustinvest ESG Evaluation - No. 1 among companies with assets of KRW 2 trillion or more — the 5th consecutive ranking No. 1 in its size grade - Published the '2025 Sustainability Report'; strengthened its management system by building an ESG data platform HK inno.N announced on July 1 that it received the highest grade (AA) in the '1H 2026 ESG Evaluation' released by ESG rating agency Sustinvest, and was ranked No. 1 among companies with assets of KRW 2 trillion or more. Sustinvest is one of Korea’s leading ESG rating agencies, conducting ESG evaluations of domestic companies in the first and second half of each year. The 1H 2026 evaluation covered 1,305 Korean companies. According to the results, HK inno.N ranked No. 1 in the KRW 2 trillion-plus asset group within the “ESG Best Companies 100” — the 100 listed companies that demonstrated outstanding performance across all environmental, social, and governance areas. With this result, HK inno.N has ranked No. 1 in its size grade for five consecutive half-year periods since the first half of 2024. Notably, the 1H 2026 evaluation was the first conducted since HK inno.N joined the group of companies with assets of KRW 2 trillion or more. Outpacing major Korean corporations, the company proved its standing as an ESG-leading firm — a result of significant meaning. In the environmental area, HK inno.N made visible its greenhouse gas reduction effect from the transition to renewable energy by signing a third-party power purchase agreement (PPA). In the social area, it systematically conducted overseas supply chain due diligence to manage its global supply chain. In the governance area, it established a CEO succession policy to build a transparent and stable management system. HK inno.N published its '2025 Sustainability Report,' which contains its ESG management strategy and performance, on June 30. The report was fully revamped from the previous horizontal layout to the vertical format, the standard disclosure form. In addition, the company built a company-wide ESG data platform, dramatically enhancing the consistency and reliability of its data. Kwak Dal-won, CEO of HK inno.N, said, “This is a meaningful result, recognizing our ESG performance not only in the pharmaceutical and bio industry but across all industries,” adding, “We will continue to take the lead in spreading sustainable value across the environmental, social, and governance areas.”

Dear investors, Detailed data from the U.S. Phase 3 clinical trials of K-CAB were presented at Digestive Disease Week 2026 from May 4 to May 5, 2026. The presented clinical data covered both erosive esophagitis (EE) treatment and maintenance therapy. In the treatment of erosive esophagitis, K-CAB demonstrated superiority over PPIs across all patient groups in terms of healing rates. In addition, K-CAB also showed differentiated superiority in maintenance therapy following the healing of erosive esophagitis. Notably, this marks the first case among P-CAB therapies to clearly demonstrate superiority over PPIs. These results provide strong evidence that K-CAB may establish a new treatment paradigm in the gastroesophageal reflux disease (GERD) market. Please refer to the links and graphs below for further details. *inno.N's press release : https://www.inno-n.com/pr/news/view/1/1101?sch_text= *Sebela(U.S. partner)'s press release : https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-presents-phase-3-tegoprazan-data-in-erosive-esophagitis-at-digestive-disease-week-ddw-2026-302762622.html *Graphs are attached.

안녕하십니까 HK이노엔 IR팀입니다. 케이캡의 미국 임상3상 상세 데이터가 DDW(Digestive Disease Week) 2026에서 5/4~5/5에 걸쳐 발표되었습니다. 발표된 임상데이터는 미란성식도염과 유지요법이며, 케이캡은 PPI 대비 미란성식도염 환자의 치유에 있어 모든 환자군에서 우월성을 입증하였으며, 미란성식도염 치유 후 유지에서도 차별화된 우월성을 입증하였습니다. 특히, P-CAB 계열 치료제 가운데 PPI 대비 우월성을 명확히 입증한 최초의 사례이며, 케이캡이 위식도 역류질환 치료 시장에서 새로운 치료 패러다임을 제시할 수 있는 근거를 확보하였습니다. 관련 상세 자료 및 그래프는 아래를 참고하여 주시기 바랍니다. * 당사 보도자료 : https://www.inno-n.com/pr/news/view/1/1101?sch_text= * 미국 파트너사 보도자료 : https://www.prnewswire.com/news-releases/sebela-pharmaceuticals-presents-phase-3-tegoprazan-data-in-erosive-esophagitis-at-digestive-disease-week-ddw-2026-302762622.html * 그래프 별첨

금일 발간된 증권사 리포트 공유드립니다. (Sharing reports published today)